JP2024513392A5 - - Google Patents

Info

Publication number
JP2024513392A5
JP2024513392A5 JP2023560497A JP2023560497A JP2024513392A5 JP 2024513392 A5 JP2024513392 A5 JP 2024513392A5 JP 2023560497 A JP2023560497 A JP 2023560497A JP 2023560497 A JP2023560497 A JP 2023560497A JP 2024513392 A5 JP2024513392 A5 JP 2024513392A5
Authority
JP
Japan
Prior art keywords
lys
cys
substituted
1peg2
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023560497A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024513392A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/022809 external-priority patent/WO2022212696A1/en
Publication of JP2024513392A publication Critical patent/JP2024513392A/ja
Publication of JP2024513392A5 publication Critical patent/JP2024513392A5/ja
Pending legal-status Critical Current

Links

JP2023560497A 2021-04-01 2022-03-31 コンジュゲートされたヘプシジン模倣物 Pending JP2024513392A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202163169538P 2021-04-01 2021-04-01
US202163169533P 2021-04-01 2021-04-01
US202163169527P 2021-04-01 2021-04-01
US63/169,538 2021-04-01
US63/169,533 2021-04-01
US63/169,527 2021-04-01
US202263325323P 2022-03-30 2022-03-30
US63/325,323 2022-03-30
PCT/US2022/022809 WO2022212696A1 (en) 2021-04-01 2022-03-31 Conjugated hepcidin mimetics

Publications (2)

Publication Number Publication Date
JP2024513392A JP2024513392A (ja) 2024-03-25
JP2024513392A5 true JP2024513392A5 (enExample) 2025-03-06

Family

ID=83456776

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023560497A Pending JP2024513392A (ja) 2021-04-01 2022-03-31 コンジュゲートされたヘプシジン模倣物

Country Status (7)

Country Link
US (1) US20250277012A1 (enExample)
EP (1) EP4314017A4 (enExample)
JP (1) JP2024513392A (enExample)
AU (1) AU2022249095A1 (enExample)
CA (1) CA3213688A1 (enExample)
TW (1) TW202304951A (enExample)
WO (1) WO2022212696A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4091624A1 (en) 2013-03-15 2022-11-23 Protagonist Therapeutics, Inc. Hepcidin analogues and uses thereof
HRP20211448T1 (hr) 2014-05-16 2021-12-24 Protagonist Therapeutics, Inc. Alfa4beta7 integrin tioeter peptidni antagonisti
CN107206254B (zh) 2014-07-17 2021-08-24 领导医疗有限公司 白细胞介素-23受体的口服肽抑制剂以及其治疗炎症性肠病的用途
CA3089868A1 (en) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
AU2021209086A1 (en) 2020-01-15 2022-08-04 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
CA3167751A1 (en) 2020-01-15 2021-07-22 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
JP7397239B2 (ja) 2020-11-20 2023-12-12 ヤンセン ファーマシューティカ エヌ.ベー. インターロイキン-23受容体のペプチド阻害剤の組成物
EP4370146A4 (en) 2021-07-14 2025-05-21 Janssen Biotech, Inc. Lipidated peptide inhibitors of the interleukin-23 receptor
EP4472996A4 (en) * 2022-02-02 2025-11-26 Protagonist Therapeutics Inc Conjugated hepcidin mimetics
EP4472995A4 (en) * 2022-02-02 2025-11-19 Protagonist Therapeutics Inc Conjugated hepcidin mimetics

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1451211A2 (en) * 2001-03-30 2004-09-01 University of Copenhagen Compositions and methods for modulating guanylyl cyclase signaling receptor (gc-c) activity and for treating meniere's disease
EP4091624A1 (en) * 2013-03-15 2022-11-23 Protagonist Therapeutics, Inc. Hepcidin analogues and uses thereof
WO2015200916A2 (en) * 2014-06-27 2015-12-30 Protagonist Therapeutics, Inc. Hepcidin and mini-hepcidin analogues and uses therof
US20190002503A1 (en) * 2015-12-30 2019-01-03 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
WO2018128828A1 (en) * 2016-12-23 2018-07-12 Bayer Healthcare Llc Novel hepcidin mimetics and uses thereof
CA3089868A1 (en) * 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
PH12022550510A1 (en) * 2019-09-03 2023-09-04 Protagonist Therapeutics Inc Conjugated hepcidin mimetics
AU2021315564A1 (en) * 2020-07-28 2023-02-09 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics

Similar Documents

Publication Publication Date Title
JP2024513392A5 (enExample)
JP2024513391A5 (enExample)
JP2023540679A5 (enExample)
JP2023536463A5 (enExample)
US12234300B2 (en) Conjugated hepcidin mimetics
US10278957B2 (en) Opioid agonist peptides and uses thereof
CN105451755B (zh) 铁调素类似物和其用途
ES2890600T3 (es) Péptidos de tioéter antagonistas de integrina alfa4beta7
CA3189432A1 (en) Conjugated hepcidin mimetics
US20240293511A1 (en) Hepcidin mimetics for treatment of hereditary hemochromatosis
JP7849383B2 (ja) コンジュゲートされたヘプシジン模倣物
JP2012530145A5 (enExample)
WO2017117411A1 (en) Analogues of hepcidin mimetics with improved in vivo half lives
JP2015533833A5 (enExample)
AU2022249095A1 (en) Conjugated hepcidin mimetics
US20240226225A1 (en) Conjugated hepcidin mimetics
KR100360975B1 (ko) 위장운동자극활성을가지는폴리펩티드
SK150196A3 (en) Peptides with immunomodulatory effects, pharmaceutical formulations containing them and their use
CN117480176A (zh) 用于治疗遗传性血色病的铁调素模拟物
EA053112B1 (ru) Конъюгированные миметики гепсидина
CN117730089A (zh) 结合型铁调素模拟物
JPS62111997A (ja) ポリペプチド
NZ751741B2 (en) Hepcidin analogues and uses therof